Long-Term Contingent Consideration Payable (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Acquisition, Contingent Consideration [Line Items]
Payments to Related Parties		$ (27,897)
Operating Expense; Acquisition-Related		30,957	$ 57,491	$ 28,135
Interest Expense; Financing-Related		4,883
Total contingent consideration		122,693	114,750
Less: Current portion		28,614	39,892
Total long-term contingent consideration payable		94,079	74,858
Warrant [Member] | Acquisition-related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[1]	34,542
Payments to Related Parties	[1]	0
Operating Expense; Acquisition-Related	[1]	(13,925)
Interest Expense; Financing-Related	[1]	0
Business Combination,Ending	[1]	20,617	34,542
Deerfield Royalty agreement [Member] | Financing Related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[2]	6,837
Payments to Related Parties	[2]	(2,282)
Operating Expense; Acquisition-Related	[2]	0
Interest Expense; Financing-Related	[2]	3,307
Business Combination,Ending	[2]	7,862	6,837
Broadfin Royalty agreement [Member] | Financing Related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[3]	3,259
Payments to Related Parties	[3]	(1,089)
Operating Expense; Acquisition-Related	[3]	0
Interest Expense; Financing-Related	[3]	1,576
Business Combination,Ending	[3]	3,746	3,259
Earn Out Payments [Member] | Acquisition-related Costs [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination,Beginning	[4]	70,112
Payments to Related Parties	[4]	(24,526)
Operating Expense; Acquisition-Related	[4]	44,882
Interest Expense; Financing-Related	[4]	0
Business Combination,Ending	[4]	$ 90,468	$ 70,112

[1] As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

[2] As part of a February 2013 debt financing transaction conducted with Deerfield Management, a related party and current shareholder, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

[3] As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

[4] As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC in March 2012, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat Pharmaceuticals products. These payments will continue in perpetuity.